Excess EGF receptors in breast cells can cause cancerous growth due to increased activity of the MAP kinase pathway. Which concept for an anti-cancer drug is least likely to work to reduce signaling through the pathway? a drug that blocks the ability of Ras to convert GTP to GDP a drug that blocks the kinase activity of the EGF receptor a drug that blocks the ability of kinases in the pathway to enter the nucleus and activate transcription factors a drug that blocks the ability of phosphatases to remove phosphates from kinases in the pathway
Added by Dylan H.
Step 1
The MAP kinase pathway is a signaling pathway that is activated by growth factors like EGF (Epidermal Growth Factor). When there are excess EGF receptors in breast cells, it leads to overactivation of this pathway, which can promote uncontrolled cell growth and Show more…
Show all steps
Your feedback will help us improve your experience
Adi S and 78 other Biology educators are ready to help you.
Ask a new question
Labs
Want to see this concept in action?
Explore this concept interactively to see how it behaves as you change inputs.
Key Concepts
Recommended Videos
Adi S.
You are studying the EGF receptor (an enzyme-linked receptor) in a cell. To study the players in the pathway, you've made several cell lines each with mutations in different members of the signaling pathways. Which of these mutations would you expect to result in an increased level of signaling in response to the EGF receptor? a. A Ras molecule with increased affinity to GDP b. A mutated PKC that can't be activated c. A mutant MAPKKK that is constitutively (always) active d. A mutant Grb2 protein that's missing its SH3 domain e. All of the above You are studying the EGF receptor (an enzyme-linked receptor) in a cell. To study the players in the pathway, you've made several cell lines each with mutations in different members of the signaling pathways. Which of these mutations would you expect to result in a lowered level of signaling in response to the EGF receptor? a. A mutant PKA that can't phosphorylate CREB b. A mutant EGF receptor that is constitutively (always) phosphorylated on its tyrosine amino acids c. A mutant Ras that can't bind to GTP d. A mutant MAPK that is constitutively (always) phosphorylated e. All of the above
Jessica W.
Ras is a GTP-binding protein that is often defective in cancer cells. A signal from a growth factor through a receptor tyrosine kinase often stimulates normal cells to divide. When the receptor tyrosine binds the growth factor , Ras is stimulated to bind GTP. Ras in turn activates proteins that promote cell proliferation. A common mutation in cancerous cells causes Ras to behave as though it were bound to GTP all the time. B. Your friend decides that the signaling pathway involving the Ras protein is a good target for drugs design, because the Ras protein is often defective in cancer cells. Your friend designs a drug that will turn off the receptor tyrosine kinase by preventing it from dimerizing. Do you think that this drug will affect cells that have a defective Ras protein that acts as if it were always bound to GTP? Why or Why not?
Madhur L.
Recommended Textbooks
Biology for AP Courses
Objective Biology for NEET
Introduction to General, Organic and Biochemistry
Transcript
Watch the video solution with this free unlock.
EMAIL
PASSWORD